Clinical results and prognostic factors of patients with locally advanced cervical carcinoma treatedwith neoadjuvant therapy followed by radical hysterectomy:a retrospective study of 182 patients
WANG Ning*, WEI Li-chun, SHI Mei, LIU Juan-yue, LI Wei-wei, LI Jian-ping, ZHANG Ying, LI Xia, HUANG Yan-hong
*Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University. Xi′an 710032, China Corresponding author:SHI Mei, mail:mshi82@fmmu.edu.cn
Abstract：Objective To analyze the clinical outcome and prognostic factors of concurrent radiochemotherapy (CRCT) or radiotherapy (RT) alone followed by radical hysterectomy in cervical cancer. Methods Between April 2006 and June 2011, 182 patients with FIGO ⅠB2-ⅢB cervical carcinoma were treated with preoperative CRCT (123 patients) or RT alone (59 patients) followed by radical surgery. Weekly cisplatin (40 mg/m2) were administered during radiotherapy for patients treated with CRCT. Preoperative RT doses were 40－50 Gy in 20－25 fractions. Total hysterosalpingo-oophorectomy and pelvic lymph node dissection was performed 2－3 weeks after neoadjuvant therapy. The prognostic factors were analyzed by Cox-regression method. Results Sixty-nine patients were followed up for 3 years. For patients with tumor ≥4.5 cm, there were no significant differences in the 3-year progression-free survival (PFS) and overall survival (OS) rates between CRCT and RT alone (χ2=1.84 and 1.56, P=0.176 and 0.221). For patients with tumor<4.5 cm, CRCT group had higher PFS and OS rates than RT alone (χ2=5.22 and 4.81,P=0.022 and 0.018). The 3-year PFS and OS rates were 92.0% and 93.8%. By multivariate analysis, tumor diameter (≥6 cm vs.<6 cm) was significant prognostic factor for PFS and OS (χ2=2.56,P=0.011;χ2=4.06,P=0.007), age (<48 vs. ≥48 years) was significant prognostic factor for OS (χ2=4.86,P=0.046), and postoperative lymph node status (positive vs. negative) was significant prognostic factor for PFS (χ2=1.04,P=0.010). Conclusions Treatment with CRCT or RT followed by radical surgery has achieved good OS and PFS for patients with FIGO ⅠB2-ⅢB cervical cancer. Tumor diameter, age and postoperative lymph node status are important prognostic factors for survival.
WANG Ning*,WEI Li-chun,SHI Mei et al. Clinical results and prognostic factors of patients with locally advanced cervical carcinoma treatedwith neoadjuvant therapy followed by radical hysterectomy:a retrospective study of 182 patients[J]. Chinese Journal of Radiation Oncology, 2012, 21(5): 448-451.
[1] Thomas G. Are we making progress in curing advanced cervical cancer? J Clin Oncol,2011,28:1654-1656. [2] Song S, Song C, Kim HJ, et al. 20 year experience of postoperative radiotherapy in ⅠB-ⅡA cervical cancer patients with intermediate risk factors:impact of treatment period and concurrent chemotherapy. Gynecol Oncol,2012,124:63-67. [3] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin,2012,62:10-29. [4] Fanfani F, Fagotti A, Ferrandina G,et al. Neoadjuvant chemoradiation followed by radical hysterectomy in FIGO Stage ⅢB cervical cancer:feasibility, complications, and clinical outcome. Int J Gynecol Cancer,2009,19:1119-1124. [5] Ferrandina G, Legge F, Fagotti A, et al. Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer:safety, outcome, and prognostic measures. Gynecol Oncol,2007,107(1 Suppl 1):127-132. [6] Mariagrazia D, Anna F, Gabriella F, et al. Preoperative chemoradiotherapy in locally advanced cervical cancer:long-term outcome and complications. Gynecol Oncol,2005,99(3 Suppl 1):166-170. [7] Macchia G, Ferrandina G, Deodato F,et al. Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix:results of a phase Ⅰ study (LARA-CC-1). Gynecol Oncol,2010,118:128-133. [8] Mancuso S, Smaniotto D, Benedetti-Panici P,et al. Phase Ⅰ－Ⅱ trial of preoperative chemoradiation in locally advanced cervical carcinoma. Gynecol Oncol,2000,78(3 Pt 1):324-328. [9] Chassagne D, Sismondi P, Horiot JC. et al. A glossary for reporting complications of treatment in gynecological cancers Radiother Oncol,1993,26:195-202. [10] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys,1995,31:1341-1346. [11] Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol,2000,18:1606-1013. [12] Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage ⅠB cervical carcinoma. N Engl J Med,1999,340:1154-1161. [13] Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med,1999,340:1137-1143. [14] Chemoradiotherapy for cervical cancer meta-analysis collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer:a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol,2008,26:5802-5812. [15] Mabuchi S, Morishige K, Isohashi F, et al. Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors. Gynecol Oncol,2009,115:482-487. [16] Dueas-González A, Zarbá JJ, Patel F, et al. Phase Ⅲ, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage ⅡB to ⅣA carcinoma of the cervix. Clin Oncol,2011,29:1678-1685. [17] Fabbro M, Gladieff L, Guichard F, et al. Phase Ⅰ study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer:a GINECO trial. Gynecol Oncol,2010,117:276-280. [18] Dueas-González A, Cetina-Perez L, Lopez-Graniel C, et al. Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer:a randomized Phase Ⅱ study. Int J Radiat Oncol Biol Phys,2005,61:817-823. [19] Pignata S, Frezza P, Tramontana S, et al. Phase Ⅰ study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri. Ann Oncol,2000,11:455-459. [20] Rao GG, Rogers P, Drake RD,et al. Phase Ⅰ clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Gynecol Oncol,2005,96:168-172. [21] Hirakawa M, Nagai Y, Toita T, et al. High-risk group for locoregional recurrence in patients with stage ⅠB-ⅡB squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy. Anticancer Res,2011,31:1437-1441. [22] Huguet F, Cojocariu OM, Levy P, et al. Preoperative concurrent radiation therapy and chemotherapy for bulky stage ⅠB2, ⅡA, and ⅡB carcinoma of the uterine cervix with proximal parametrial invasion. Int J Radiat Oncol Biol Phys,2008,72:1508-1515. [23] Kirova YM, Bourhaleb Z, Alran S, et al. Preoperative concomitant radiochemotherapy in bulky carcinoma of the cervix:institut gurie experience. Cancer Radiother,2009,13:291-297. [24] Colombo PE, Bertrand MM, Gutowski M, et al. Total laparoscopic radical hysterectomy for locally advanced cervical carcinoma (stages ⅡB, ⅡA and bulky stages ⅠB) after concurrent chemoradiation therapy:surgical morbidity and oncological results. Gynecol Oncol,2009,114:404-409. [25] Classe JM, Rauch P, Rodier JF, et al. Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer:morbidity and outcome:results of a multicenter study of the GCCLCC. Gynecol Oncol,2006,102:523-529.
2012, Vol. 21 
